JP2023523241A5 - - Google Patents
Info
- Publication number
- JP2023523241A5 JP2023523241A5 JP2022564258A JP2022564258A JP2023523241A5 JP 2023523241 A5 JP2023523241 A5 JP 2023523241A5 JP 2022564258 A JP2022564258 A JP 2022564258A JP 2022564258 A JP2022564258 A JP 2022564258A JP 2023523241 A5 JP2023523241 A5 JP 2023523241A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025156540A JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014001P | 2020-04-22 | 2020-04-22 | |
| US63/014,001 | 2020-04-22 | ||
| PCT/US2021/028323 WO2021216656A1 (en) | 2020-04-22 | 2021-04-21 | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156540A Division JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523241A JP2023523241A (ja) | 2023-06-02 |
| JP2023523241A5 true JP2023523241A5 (https=) | 2024-05-02 |
| JP7830347B2 JP7830347B2 (ja) | 2026-03-16 |
Family
ID=75919388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564258A Active JP7830347B2 (ja) | 2020-04-22 | 2021-04-21 | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 |
| JP2025156540A Pending JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025156540A Pending JP2025186437A (ja) | 2020-04-22 | 2025-09-19 | Ｈｂｖの処置のための５員のヘテロアリールカルボキサミド化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230183213A1 (https=) |
| EP (1) | EP4139292A1 (https=) |
| JP (2) | JP7830347B2 (https=) |
| KR (1) | KR20230005881A (https=) |
| CN (2) | CN121248511A (https=) |
| AR (1) | AR121905A1 (https=) |
| AU (1) | AU2021261307A1 (https=) |
| BR (1) | BR112022021419A2 (https=) |
| CA (1) | CA3180706A1 (https=) |
| IL (1) | IL297305A (https=) |
| MX (1) | MX2022013251A (https=) |
| PH (1) | PH12022552815A1 (https=) |
| TW (1) | TW202206415A (https=) |
| WO (1) | WO2021216656A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023069544A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069545A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069547A1 (en) * | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| AU2022370483A1 (en) * | 2021-10-20 | 2024-05-02 | Assembly Biosciences, Inc. | Novel crystalline forms |
| EP4419519A4 (en) * | 2021-10-20 | 2025-09-10 | Assembly Biosciences Inc | PROCESS |
| WO2023111996A1 (en) | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| EP2800742B1 (en) | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| EA026957B1 (ru) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
| CA2881322A1 (en) | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| WO2014089296A2 (en) | 2012-12-06 | 2014-06-12 | Institute For Hepatitis And Virus Research | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| BR112015015584A2 (pt) | 2012-12-27 | 2017-12-12 | Baruch S Blumberg Inst | novos agentes antivirais contra infecção por hbv |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| BR112015028873A2 (pt) | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
| DK2997019T3 (en) | 2013-05-17 | 2018-12-03 | Janssen Sciences Ireland Uc | SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| HRP20180791T1 (hr) * | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| ES2748029T3 (es) * | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| TWI721016B (zh) * | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| KR102398439B1 (ko) * | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| EP3478692B1 (en) * | 2016-06-29 | 2020-06-17 | Novira Therapeutics Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| AU2017326356A1 (en) * | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| KR20200074971A (ko) | 2017-10-19 | 2020-06-25 | 제이에스 이노팜 (상하이) 리미티드 | 헤테로사이클릭 화합물, 헤테로사이클릭 화합물을 포함하는 조성물 및 그의 사용 방법 |
| CA3117449A1 (en) | 2018-10-22 | 2020-04-30 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
-
2021
- 2021-04-21 CN CN202511217514.7A patent/CN121248511A/zh active Pending
- 2021-04-21 US US17/920,544 patent/US20230183213A1/en active Pending
- 2021-04-21 JP JP2022564258A patent/JP7830347B2/ja active Active
- 2021-04-21 PH PH1/2022/552815A patent/PH12022552815A1/en unknown
- 2021-04-21 EP EP21725867.2A patent/EP4139292A1/en active Pending
- 2021-04-21 CA CA3180706A patent/CA3180706A1/en active Pending
- 2021-04-21 BR BR112022021419A patent/BR112022021419A2/pt unknown
- 2021-04-21 CN CN202180042939.2A patent/CN115843294B/zh active Active
- 2021-04-21 AR ARP210101072A patent/AR121905A1/es unknown
- 2021-04-21 KR KR1020227040228A patent/KR20230005881A/ko active Pending
- 2021-04-21 IL IL297305A patent/IL297305A/en unknown
- 2021-04-21 WO PCT/US2021/028323 patent/WO2021216656A1/en not_active Ceased
- 2021-04-21 MX MX2022013251A patent/MX2022013251A/es unknown
- 2021-04-21 AU AU2021261307A patent/AU2021261307A1/en active Pending
- 2021-04-22 TW TW110114601A patent/TW202206415A/zh unknown
-
2025
- 2025-09-19 JP JP2025156540A patent/JP2025186437A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023523241A5 (https=) | ||
| JP2022508953A5 (https=) | ||
| JP2017537949A5 (https=) | ||
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| JP2009512719A5 (https=) | ||
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2005532389A5 (https=) | ||
| JP2006506443A5 (https=) | ||
| JP2008510771A5 (https=) | ||
| JP2007532479A5 (https=) | ||
| JP2014531449A5 (https=) | ||
| RU2007123235A (ru) | Противоопухолевые соединения | |
| JP2015526468A5 (https=) | ||
| JP2017523169A5 (https=) | ||
| RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| RU2015110082A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP2017505314A5 (https=) | ||
| JP2005504042A5 (https=) | ||
| RU2003129638A (ru) | Новые соединения | |
| JP2018514544A5 (https=) | ||
| JP2013544276A5 (https=) | ||
| JP2019527724A5 (https=) | ||
| RU2018114077A (ru) | Биарильное производное и содержащее его лекарственное средство | |
| RU2017105902A (ru) | Соединения для применения в дегельминтизации |